Business
– Multiple sclerosis treatment Copaxone accounts for an estimated half of Teva’s profit. – Changes in the multiple sclerosis treatment market, in which...
Hi, what are you looking for?
– Multiple sclerosis treatment Copaxone accounts for an estimated half of Teva’s profit. – Changes in the multiple sclerosis treatment market, in which...
– Sales of the multiple sclerosis treatment were down 12% in the second quarter. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported...
– Glass Lewis even recommends against board motions to which Benny Landa has not objected. A day after ISS recommended investors to support Teva...
See also: Teva Pharmaceuticals Denies Picking New Chairman – I am an industrialist, not a financial investor. I focus on running my own...
– Enabling the Global Integration of the Company and Positioning It for Short- and Long-Term Value Creation. – – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE: TEVA)...
– Teva investors are concerned about competition to the company’s Copaxone medication now that its patent has expired. Due to its failed attempt recently...
– Bonuses could boost Erez Vigodman’s compensation to $4.1 million annually, not including options. – – The basic salary of incoming Teva Pharmaceutical Industries Ltd. (NYSE:TEVA;...
– – Teva Pharmaceutical Industries Ltd (NYSE:TEVA) today announced that Erez Vigodman, 54, has been appointed President and Chief Executive Officer, effective February 11,...
– Teva’s board is due to meet within days to approve Erez Vigodman’s appointment as CEO. – – Erez Vigodman, 54, a board member...
– In an email to investors seen by the “Financial Times, ” printing pioneer Benny Landa hints he is seeking to oust Teva chairman...